Eagle Pharmaceuticals is delaying the release of its Q3 results

Eagle Pharmaceuticals announced that it will be delaying the release of its third quarter 2023 results and investor conference call, previously scheduled for today, Thursday, November 9, 2023. The Company currently anticipates filing a Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commission no later than one business day after the due date of its Quarterly Report on Form 10-Q for the third quarter ended September 30, 2023, and expects to file its Form 10-Q by November 14, 2023, prior to the expiration of the extension period provided by Rule 12b-25 under the Securities Exchange Act of 1934. The Company requires more time to review potential adjustments relating to the reporting of sales of PEMFEXY prior to filing its Form 10-Q. In addition, the Company expects to revise its previously disclosed 2023 full year guidance downward. “We remain confident in the strength of our business and our outlook for 2024, and we look forward to reporting on our commercial portfolio, progress on our pipeline and other initiatives,” stated Scott Tarriff, President and CEO of Eagle.